BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Lipocine Inc. 

675 Arapeen Drive
Suite 202
Salt Lake City  Utah  84108  U.S.A.
Phone: 801-994-7383 Fax:


SEARCH JOBS










 Company News
Lipocine Inc. (LPCN) Announces First Patient Dosed In Phase 1 Study In Pregnant Women Of LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth 9/9/2014 7:23:31 AM
Lipocine Inc. (LPCN) Announces Financial And Operational Results For The Second Quarter Of 2014 8/13/2014 3:54:45 PM
Lipocine Inc. (LPCN) Announces Issuance Of U.S. Patent For LPCN 1021 7/16/2014 5:46:46 AM
Lipocine Inc. (LPCN) Added To Russell Microcap Index 6/30/2014 7:42:45 AM
Lipocine Inc. (LPCN) To Present At The Jefferies and Co. 2014 Global Healthcare Conference 5/30/2014 9:19:20 AM
Lipocine Inc. (LPCN) Announces First Patient Dosed In Phase 2a Study Of LPCN 1111, A Novel Testosterone Ester For Oral Testosterone Replacement Therapy 5/28/2014 9:22:33 AM
Lipocine Inc. (LPCN) Announces Successful Phase 1 Results With LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth 5/15/2014 11:36:07 AM
Lipocine Inc. (LPCN) Announces Successful Phase 1 Results With LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth 5/15/2014 9:44:07 AM
Lipocine Inc. (LPCN) Announces Completion Of Enrollment In Its SOAR Phase 3 Study For Oral Testosterone Replacement Therapy 4/29/2014 9:22:45 AM
Lipocine Inc. (LPCN) To Begin Trading On The NASDAQ Capital Market 3/18/2014 9:02:37 AM
123